Complete the form to take advantage of the following offers
Get Divigel® samples for your office

If you are a physician or other healthcare professional in the U.S. or Puerto Rico, you can receive Divigel® samples by mail to support patient trial and use.

To receive samples by mail, please follow these steps:

  1. Fill in the information to the right and click Submit
  2. Print and sign the confirmation form—your signature and the date are required to authorize samples
  3. Fax the completed confirmation form to Vertical Pharmaceuticals, LLC at 1-866-315-4753
Click here to access the Divigel® Patient Savings Coupon
Schedule a visit with a Divigel® representative

If you would like to hear more about Divigel® from a sales representative, someone will be in touch with you shortly to set up a time for a visit.

You must fill in all required fields.
*Required
*
*
*
*
*
*
*
 * 
 * 
*
*
Where did you first hear about Divigel®?
*
If you are unable to complete your sample request, please call 1-866-600-4799 for assistance.
You may unsubscribe from communications at any time.
Vertical Pharmaceuticals, LLC respects your interest in keeping your personal and professional information private. We will not sell or rent your information.

For details on how your personal information may be used, please review our Privacy Policy.

If you are unable to complete your sample request, please contact our Sales Service Department toll free at 1-800-654-2299 for assistance.

You may unsubscribe from communications at any time.

Vertical Pharmaceuticals, LLC respects your interest in keeping your personal and professional information private. We will not sell or rent your information.

For details on how your personal information may be used, please review our Privacy Policy.
Divigel® (estradiol gel) 0.1% is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Important Safety Information for Healthcare Providers

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA

See Full Prescribing Information for complete Boxed Warning

Estrogen-Alone Therapy
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
  • The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
  • The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age or older
Estrogen Plus Progestin Therapy
  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
  • The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI)
  • The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
  • The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Divigel® should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema to Divigel®; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; or known or suspected pregnancy.

Estrogens increase the risk of gallbladder disease.

Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs.

Monitor thyroid function in women on thyroid replacement therapy.

The most common adverse reactions (incidence ≥ 5 percent) are breast tenderness, metrorrhagia, vaginal mycosis, nasopharyngitis, and upper respiratory tract infection.

Patients should be started with the lowest effective dose and the dose should be evaluated periodically.

Alcohol-based gels are flammable. Patients should avoid fire, flame or smoking until the gel has dried.

Please see Full Prescribing Information, including Boxed Warning and Patient Counseling Information. For more information, call 732-721-0070 or visit www.divigel.com.

You are encouraged to report negative side effects to Vertical Pharmaceuticals, LLC at 1-877-95-VERTI (1-877-958-3784), or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Important Safety Information & Indication
Divigel® (estradiol gel) 0.1% is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Important Safety Information for Healthcare Providers

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA

See Full Prescribing Information for complete Boxed Warning

Estrogen-Alone Therapy
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
  • The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
  • The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age or older
Estrogen Plus Progestin Therapy
  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
  • The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI)
  • The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
  • The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Divigel® should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema to Divigel®; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; or known or suspected pregnancy.

Estrogens increase the risk of gallbladder disease.

Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs.

Monitor thyroid function in women on thyroid replacement therapy.

The most common adverse reactions (incidence ≥ 5 percent) are breast tenderness, metrorrhagia, vaginal mycosis, nasopharyngitis, and upper respiratory tract infection.

Patients should be started with the lowest effective dose and the dose should be evaluated periodically.

Alcohol-based gels are flammable. Patients should avoid fire, flame or smoking until the gel has dried.

Please see Full Prescribing Information, including Boxed Warning and Patient Counseling Information. For more information, call 732-721-0070 or visit www.divigel.com.

You are encouraged to report negative side effects to Vertical Pharmaceuticals, LLC at 1-877-95-VERTI (1-877-958-3784), or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.